^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Solid Tumor
    Drug:Tarlox (tarloxotinib bromide) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    NSCLC Exon 20 or HER2-activating Mutations

    Excerpt:
    ...- EGFR exon 20 insertion mutation (Cohort A) or HER2-activating mutation (Cohort B)...
    Trial ID:
    RAIN
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

    Excerpt:
    ...- EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fusions (Cohort C)...
    Trial ID:
    RAIN
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

    Published date:
    12/22/2020
    Excerpt:
    Novel and existing patient-derived cell lines and xenografts harboring EGFR exon 20 insertion mutations, ERBB2 (HER2) mutations and amplification, and NRG1 fusions were tested in vitro and in vivo with tarloxotinib...Tarloxotinib-E inhibited cell signaling and proliferation in patient-derived cancer models in vitro...In vivo, tarloxotinib induced tumor regression or growth inhibition in multiple murine xenograft models.
    DOI:
    10.1158/1078-0432.CCR-20-3555